| TJC0545 |
The lead compound of the series development has been discovered and is currently under lead optimization process. The mechanism of action (MOA) of this project is a newly developed dual-target inhibitions (i.e., First-in-Class). Cell cytotoxicity and xenograft anti-cancer efficacy have been confirmed. More of such tests are under process.